Navigation Links
BioMarin Receives Positive Opinion from European Regulatory Authorities for Expanded Biologics Manufacturing Facility
Date:12/19/2011

NOVATO, Calif., Dec. 19, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for the company's manufacturing facility expansion in Novato, CA.  Final approval by the EMA is expected in the first quarter of 2012, which would allow for products manufactured at the facility to be distributed in the European Union.  The two Novato facilities will support up to $1.0 billion in revenue for BioMarin's growing enzyme replacement therapy portfolio. 

"We are pleased that the CHMP has recommended a positive opinion for the expanded Novato manufacturing facility on the heels of the FDA approval in late November," stated Jean-Jacques Bienaime, Chief Executive Officer of BioMarin.  "As our commercial products continue to grow and our pipeline advances, this state-of-the-art facility will help support the manufacturing requirements for anticipated peak sales of our commercial products and several of our clinical and pre-clinical programs."

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine), which has been
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Highlights from BioMarins Research & Development Day
2. BioMarin Announces Buy Back of Naglazyme Royalties From Adelaide Health Authority
3. BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA
4. BioMarin Announces FDA Approval of Expanded Biologics Manufacturing Facility
5. BioMarin to Host a Research and Development Day on December 8th
6. BioMarin Announces Third Quarter 2011 Financial Results
7. BioMarin to Present at the UBS Global Life Sciences Conference
8. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
9. BioMarin to Present at the Baird Health Care Conference
10. BioMarin to Present at the Wedbush Life Sciences Conference
11. BioMarin Announces Second Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Research ... "Global and Chinese Medical X-ray Film Industry Report ... http://photos.prnewswire.com/prnh/20130307/600769 Global And Chinese ... and in-depth study on the current state of the ... the Chinese situation. The report provides a basic ...
(Date:7/11/2014)... 2014  Australian drug delivery company, Phosphagenics Limited (ASX: ... A$19.3 million via a placement of A$16.3 million to ... U.S., Asia and ... purchase plan (SPP) to be offered to existing shareholders. ... two tranches. "This capital raising positions us ...
(Date:7/11/2014)... , July 11, 2014  Veran ... company, announced today the positive, cost-effective final ... innovative SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous ... a percutaneous approach to biopsy when a ... patients and physicians experience positive financial outcomes ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Veran Medical Publishes Lung Cancer Patient Management Study 2
... presented this week at the International Federation of Clinical ... lower diagnostic threshold for troponin improves clinical outcomes and ...  Troponin is a protein found inside of heart cells ... or reduced blood supply.   Cardiac troponin ...
... 18, 2011 The core technology of ViewRay™, Inc., ... radiotherapy technologies, has been issued landmark patents in the ... device company, holds the exclusive worldwide license for the ... technology was invented by company founder James F. Dempsey, ...
Cached Medicine Technology:Study Shows Improved Patient Management and Outcome Using Abbott's Sensitive Troponin Assay 2Study Shows Improved Patient Management and Outcome Using Abbott's Sensitive Troponin Assay 3Study Shows Improved Patient Management and Outcome Using Abbott's Sensitive Troponin Assay 4Landmark Patents Issued for ViewRay Technology 2
(Date:7/13/2014)... 14, 2014 Worldwide ladies are extremely ... Angeldress.co.uk has taken a different approach and has created ... are offered in more colour choices that responded directly ... brand of women’s special occasion apparels. The company’s pink ... specialists are working hard to create the best products ...
(Date:7/13/2014)... 13, 2014 Carolinas Healthcare System celebrated ... the Carolinas HealthCare System - Anson located in Anson ... Anson Community Hospital in Wadesboro. , Located on U.S. ... from the previous facility. Situated on a 10-acre site, ... an emergency room drop-off, helipad, healing garden, and 15 ...
(Date:7/13/2014)... July 13, 2014 Recently, MillionaireCasket.com, a well-known ... oak caskets . Additionally, the company’s chief executive officer ... the new oak caskets are offered at discounted prices, from ... am concerned, quality caskets are in huge demand in the ... caskets . We have a lot of high quality ...
(Date:7/13/2014)... 13, 2014 Advanced boilers are ... least amount of fossil fuels, produce high-capacity power, ... to increased global warming and climate change concerns, ... reduce harmful gas emissions and pollutants coming from ... in the global advance boilers market., The global ...
(Date:7/13/2014)... Serena Gordon HealthDay ... A new type of sensor for people with diabetes ... using saliva instead of blood, researchers report. Scientists at ... tested it using artificial saliva. It uses light, metal and ... sugar. "Everybody knows that diabetics have to prick their ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Announces Summer Sale For Pink And Red Bridesmaid Dresses; The Current Discount Is Up To 80% Off 2Health News:Carolinas HealthCare System - Anson Hospital Now Open 2Health News:Cheap Oak Caskets Recently Unveiled By China Casket Manufacturer MillionaireCasket.com 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 3Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3
... N.C. Older adults who take drugs designed to ... incontinence, high blood pressure and allergies are more ... of daily living and to walk slower, according to ... of Medicine and colleagues. , The findings, which involve ...
... find decongestants and antihistamines taken most often , , ... 10 U.S. children uses one or more cough and ... research from Boston University. , While cough and cold ... States, how frequently they are used had not been ...
... 2 The following is,being issued today by ... will launch an unfair labor practice strike against,Inter-Con ... 6. This is the,first-ever group of hospital security ... on workers who were trying to form a,union ...
... Inc.,(Nasdaq: OSTE ) announces today that on April ... response to its notification to Nasdaq that,Robert W. Gunn, ... of,Directors, Audit and Compensation Committees, passed away unexpectedly on,April ... independent directors,serving on its Audit Committee and is not ...
... has already worked against breast, colon cancers , , FRIDAY, ... new targets for treatments that block tumor blood vessel ... metastasis -- have been identified by researchers at the ... use of the drug bevacizumab (Avastin) to target the ...
... 2 American Pacific Corporation,(Nasdaq: APFC ) today ... financial results on Thursday, May 8, 2008. John R. ... in a,teleconference to review the financial results and outlook ... Thursday, May 8, 2008 at 1:30 p.m. PDT.,To access ...
Cached Medicine News:Health News:Commonly used medications associated with impaired physical function in older adults 2Health News:10% of U.S. Kids Using Cough Medicine Every Week 2Health News:First-Ever Group of Hospital Security Officers to Strike over Unfair Labor Practices, Walk out of Facilities Across California on May 6 2Health News:Osteotech Announces the Unexpected Passing of Audit Committee Member Leads to Receipt of Nasdaq Deficiency Letter 2Health News:New Targets Found That Stop Tumor Growth 2Health News:American Pacific to Release Financial Results and Hold Fiscal 2008 Second Quarter Investor Teleconference 2
1000L...
... fixed pipette is ideal for ... volume. Fixed volume FInnpipettes offer ... as other Finnpipette Digital pipettes: ... blow-out (1-40ul), Soft-touch tip ejection, ...
Inquire...
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
Medicine Products: